Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 5Thoracic 3Plasma cell 3Gastrointestinal 3Breast 3Tumor-Agnostic 2Head & Neck 2Sarcoma 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Endocrine 1CNS 1

Conditions

Stomach Neoplasms 2Weight Loss 1Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cachexia 1Anorexia 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Olanzapine × Gastrointestinal × Clear all
NCT07581405 2026-05-12

GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer

University of Illinois at Chicago

Phase 2 Not yet recruiting
26 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05705492 2026-01-21

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
66 enrolled
Gastrointestinal

Anorexia, Cachexia, Esophageal Neoplasms, Neoplasms, Colorectal Neoplasms, Weight Loss

NCT03575637 2018-07-03

Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer

Peking University

Phase 2 Unknown
180 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡